Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Slides:

Advertisements

Similar presentations

The ability of gut microbiota to communicate with the brain and thus modulate behavior is emerging as an exciting concept in health and disease. Specific.

Advertisements

Pg-Certificate CBT-2017 Dr.Bashir Ahmad (Course Director)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Low-grade inflammation in FGID

Figure 4 The gut microbiota directly influences T-cell differentiation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Interactions between adipose, the microbiome and kidney

Figure 1 Contribution of the gut microbiota

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Gut microorganisms at the intersection of several diseases

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The microbiome–gut–brain axis

Figure 7 Clinical options for HCC therapy

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 The T-cell cytokine tree in IBD

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Algorithm from working group describing

Figure 3 The 'leaky gut' hypothesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Schematic outlining the results of Buffington et al.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Microbiome at the Frontier of Personalized Medicine

Figure 1 Host range of hepatitis E virus

Figure 2 Switching of biologic agents and biosimilars

Figure 2 Brain networks contributing to IBS symptoms

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 An overview of the TIMER microbiota–host

Microbiome at the Frontier of Personalized Medicine

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Figure 1 Tropical sprue and PI-IBS

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 A model for the future analysis

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 2 Key brain–immune–gut interactions

Figure 1 The role of CTLA4 and PD1 in T cell activation

Cross-sectional integrated brain–gut model of IBS pathophysiology

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 New therapeutic approaches in IBD with their specific targets

Figure 5 Systems biological model of IBS

Figure 1 Mucosal immune networks

Figure 4 Local species pools that contribute to the

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 Colonic inflammation in IBD and link to the gut microbiota

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Presentation transcript:

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis Figure 5 | Therapeutic paradigms for interfering with the brain–gut axis. Interventions directed at either the brain or gut aspect of the axis might be anticipated to alleviate clinical features in both organ systems. For example, in patients in whom gut symptoms are primarily driving brain symptoms, modulation of the microbiota (e.g. faecal microbiota transplantation (FMT) or probiotic therapy) would directly alter host immune responses, alleviate local immune activation and simultaneously reduce immune-driven brain dysfunction. Likewise, targeting the stress response (e.g. psychotherapy or antidepressants) would alleviate brain symptoms, but would also limit autonomic activation of host immunity to suppress aberrant immune-driven gut symptoms. CBT, cognitive behavioural therapy; mAb, monoclonal antibody. Powell, N. et al. (2017) The mucosal immune system: master regulator of bidirectional gut–brain communications Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2016.191